Summary
- Profile Type
- Technology offer
- POD Reference
- TOGB20250313010
- Term of Validity
- 13 March 2025 - 13 March 2026
- Company's Country
- United Kingdom
- Type of partnership
- Commercial agreement with technical assistance
- Research and development cooperation agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- An innovative UK company offers a data-driven software solution for rapidly identifying suitable patients for liver disease clinical trials using existing blood test data. The company seeks pharmaceutical partners for commercial agreements with technical assistance to conduct clinical trials.
- Full Description
-
The company established in 2019, has developed a data-driven case-finding solution for the early identification of liver disease.
The company’s solution analyses years of blood test results already present in healthcare systems to identify patterns and trends indicative of potential liver disease. The system empowers clinicians to proactively find patients for early intervention and prevention.
The intellectual property (IP) is owned by an NHS Foundation Trust (UK National Health Service) and licensed to the company. This is not a system that uses complex artificial intelligence, but structures and presents data in a way that is readily accessible to clinicians.
The company's innovative approach analyses longitudinal trends in blood test results to identify individuals at risk of, or with, undiagnosed liver disease. This proactive method addresses the challenge of late or missed diagnoses, common with liver disease. The system uses client provided data to identify patients and enables clinicians without specialist data analytics skills to identify cohorts of individuals with historic blood test results that indicate poor liver health. The system is designed to be easily implemented across the healthcare system, mapping multiple data sources and linking patient information by the patient identifier (NHS number).
The company is seeking commercial partners with technical, possibly research, assistance to conduct clinical trials for liver disease. - Advantages and Innovations
-
The system offers several key advantages for pharmaceutical companies engaged in clinical trials. It provides rapid patient identification, generating cohorts of patients meeting specific criteria in seconds, which significantly speeds up patient recruitment.
The system is also cost-effective, utilizing existing patient data and eliminating the need for additional testing, thereby reducing the costs associated with identifying suitable trial participants.
It allows for targeted recruitment, identifying patients based on various criteria such as specific biomarkers, residence, and indices of deprivation, which enables more focused and efficient trial recruitment.
The system has demonstrated proven efficacy through pilot studies, successfully identifying individuals with Primary Biliary Cholangitis (PBC), advanced fatty liver disease, and hepatitis, and has already identified over 700 patients for further investigation and treatment, with 100 high-risk patients seen in clinic to date. By accelerating patient recruitment, the solution contributes to a reduced time to market for new treatments.
Furthermore, it is designed for easy implementation and use by clinicians, without requiring specialized data analytics expertise.
The company has secured Section 251 approval from the national (NHS) Confidentiality Advisory Group which means that there is consent for using personally identifiable data both for treatment and research.
The company has secured Class I Medical Device registration for the software in the UK with the MHRA and in the EU with EUDAMED. - Stage of Development
- Already on the market
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
Partner Sought
- Expected Role of a Partner
-
The company seeks partnerships with pharmaceutical companies and Contract Research Organisations (CROs) conducting clinical trials for liver disease. The partner’s role would be to:
• Engage with the company to define cohort criteria for specific trials.
• Access the generated cohorts using the system once patient consent to participate in trials has been secured.
• Manage patient recruitment and data collection processes with the support of the system. - Type and Size of Partner
- SME <=10
- SME 11-49
- SME 50 - 249
- Big company
- R&D Institution
- University
- Other
- Type of partnership
- Commercial agreement with technical assistance
- Research and development cooperation agreement
Dissemination
- Technology keywords
- 01004001 - Applications for Health
- 06001002 - Clinical Research, Trials
- 06001005 - Diagnostics, Diagnosis
- Market keywords
- 05001007 - Other diagnostic
- 05007007 - Other medical/health related (not elsewhere classified)
- 02006004 - Data processing, analysis and input services
- Sector Groups Involved
- Health
- Targeted countries
- All countries